These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27230923)

  • 81. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
    Nurmi E; Bergman J; Eskola O; Solin O; Hinkka SM; Sonninen P; Rinne JO
    J Cereb Blood Flow Metab; 2000 Nov; 20(11):1604-9. PubMed ID: 11083235
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study.
    Yamasaki T; Fujinaga M; Kawamura K; Furutsuka K; Nengaki N; Shimoda Y; Shiomi S; Takei M; Hashimoto H; Yui J; Wakizaka H; Hatori A; Xie L; Kumata K; Zhang MR
    J Neurosci; 2016 Jan; 36(2):375-84. PubMed ID: 26758830
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease.
    Delva A; Van Weehaeghe D; Koole M; Van Laere K; Vandenberghe W
    Mov Disord; 2020 Nov; 35(11):1977-1986. PubMed ID: 32767618
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).
    Guilloteau D; Emond P; Baulieu JL; Garreau L; Frangin Y; Pourcelot L; Mauclaire L; Besnard JC; Chalon S
    Nucl Med Biol; 1998 May; 25(4):331-7. PubMed ID: 9639293
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.
    Hall H; Halldin C; Guilloteau D; Chalon S; Emond P; Besnard J; Farde L; Sedvall G
    Neuroimage; 1999 Jan; 9(1):108-16. PubMed ID: 9918732
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
    Delva A; Van Laere K; Vandenberghe W
    Mov Disord; 2022 Sep; 37(9):1883-1892. PubMed ID: 35819412
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
    Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
    Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072
    [TBL] [Abstract][Full Text] [Related]  

  • 89. "Depressed" caudate and ventral striatum dopamine transporter availability in de novo Depressed Parkinson's disease.
    Yoo SW; Oh YS; Hwang EJ; Ryu DW; Lee KS; Lyoo CH; Kim JS
    Neurobiol Dis; 2019 Dec; 132():104563. PubMed ID: 31377233
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Simplified estimation of binding parameters based on image-derived reference tissue models for dopamine transporter bindings in non-human primates using [
    Odano I; Varrone A; Hosoya T; Sakaguchi K; Gulyás B; Padmanabhan P; Ghosh KK; Yang CT; Guenther I; Wang Z; Serrano R; Chimon NG; Halldin C
    Am J Nucl Med Mol Imaging; 2017; 7(6):246-254. PubMed ID: 29348979
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
    Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
    Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease.
    Ribeiro MJ; Vidailhet M; Loc'h C; Dupel C; Nguyen JP; Ponchant M; Dollé F; Peschanski M; Hantraye P; Cesaro P; Samson Y; Remy P
    Arch Neurol; 2002 Apr; 59(4):580-6. PubMed ID: 11939892
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Measurement of the striatal dopamine transporter density and heterogeneity in type 1 alcoholics using human whole hemisphere autoradiography.
    Tupala E; Kuikka JT; Hall H; Bergström K; Särkioja T; Räsänen P; Mantere T; Hiltunen J; Vepsäläinen J; Tiihonen J
    Neuroimage; 2001 Jul; 14(1 Pt 1):87-94. PubMed ID: 11525341
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Increased DAT binding in the early stage of the dopaminergic lesion: a longitudinal [11C]PE2I binding study in the MPTP-monkey.
    Vezoli J; Dzahini K; Costes N; Wilson CR; Fifel K; Cooper HM; Kennedy H; Procyk E
    Neuroimage; 2014 Nov; 102 Pt 2():249-61. PubMed ID: 25108180
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Synthesis of 3H-labeled N-(3-iodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4-methylphenyl)nortropane (PE2I) and its interaction with mice striatal membrane fragments.
    Stepanov V; Schou M; Järv J; Halldin C
    Appl Radiat Isot; 2007 Mar; 65(3):293-300. PubMed ID: 17081763
    [TBL] [Abstract][Full Text] [Related]  

  • 96. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
    J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
    [TBL] [Abstract][Full Text] [Related]  

  • 97. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.
    Masilamoni G; Votaw J; Howell L; Villalba RM; Goodman M; Voll RJ; Stehouwer J; Wichmann T; Smith Y
    Exp Neurol; 2010 Dec; 226(2):265-73. PubMed ID: 20832405
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Potential of [(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in the conscious monkey brain.
    Harada N; Ohba H; Fukumoto D; Kakiuchi T; Tsukada H
    Synapse; 2004 Oct; 54(1):37-45. PubMed ID: 15300883
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease.
    Tinaz S; Chow C; Kuo PH; Krupinski EA; Blumenfeld H; Louis ED; Zubal G
    Clin Nucl Med; 2018 Jan; 43(1):e1-e7. PubMed ID: 29112012
    [TBL] [Abstract][Full Text] [Related]  

  • 100. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
    J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.